Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Rosu – page 8

227 clinical trials in Rosu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Rosu at a glance
227
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

227 trials in Rosu

Open in trial search

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Mocravimod for Adults with Acute Myeloid Leukemia Undergoing Stem Cell Transplant

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Mocravimod
  • Sponsor:Priothera S.A.S.

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness and Safety of Metronidazole, Neomycin Sulfate, and Nystatin for Women with Bacterial Vaginosis and Yeast Infections

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Metronidazole
  • Sponsor:Antibiotice S.A.

Pneumonia

Recruiting

Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Baloxavir Marboxil
  • Sponsor:University Of Oxford

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Rosu

What the registry says about research in the country

01 Cardiovascular Disease – Atrial Fibrillation

Research in Rosu is centered on a common heart rhythm disorder that raises the chance of serious vascular events.

  • Evaluation of REGN7508 compared with standard anticoagulant therapy
  • Combined REGN7508 and REGN9933 versus placebo
  • Risk assessment of clinically relevant bleeding
  • Stroke and systemic embolism prevention for patients unsuitable for oral anticoagulation

The trials aim to expand treatment choices and lower the incidence of stroke and embolic complications in atrial fibrillation.

02 Anticoagulation Safety in Atrial Fibrillation

Ongoing studies examine how to protect patients from ischemic stroke while reducing the likelihood of major bleeding events.

  • Comparison of bleeding risk between experimental agents and apixaban
  • Evaluation of major bleeding outcomes with dual‑target therapy
  • Analysis of stroke prevention effectiveness in high‑risk cohorts
  • Safety profiling for participants unable to use conventional oral anticoagulants

Findings are expected to inform safer anticoagulation strategies for individuals living with atrial fibrillation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.